Effectiveness of Local Delivery of Alendronate in Reducing Alveolar Bone Loss Following Periodontal Surgery in Rats

Authors:
  • MAM. Adut
    M. Adut
  • AYA. Yaffe
    A. Yaffe

Abstract
Background: Mucoperiosteal flaps are used to access bone and root surfaces for debridement, pocket elimination, management of periodontal defects, and in regenerative procedures, as well as in implant surgery. Many reports show that periodontal surgery stimulates osteoclast activity with varying amounts of alveolar bone loss. Alendronate given intravenously significantly reduced alveolar bone loss in mucoperiosteal flap procedures. In the present study, we explored the effectiveness of different concentrations of alendronate, delivered at the surgical site at the time of surgery, in distant delivery in reducing alveolar bone loss.Methods: Following elevation of a mucoperiosteal flap next to molars of the rat mandible, a gelatin sponge soaked with different concentrations of alendronate (0, 1, 5, 20, or 40 mg/ml; experiment A) was applied to exposed bone on the experimental side. In the second group (experiment B), alendronate (0, 50, 200, or 400 µg) was topically delivered in the cheek submucosa on the left side (distant to the surgical site) in a small cut into which the gelatin sponge soaked with the drug was placed.Results: Topical application of 200 µg and 400 µg doses of alendronate at the time of surgery was significantly effective (P Conclusions: This study implies that topical delivery of alendronate at the time of surgery reduces bone loss in periodontal procedures involving mucoperiosteal flap surgery. The most effective dose is 200 µg for topical delivery at the surgical site and 400 µg for distant sites. J Periodontol 2000;71:1236‐1240.

This publication has 21 references indexed in Scilit: